Target range typically 5001000 mcg daily during loading phase
How do peptide therapies compare to conventional methods for AMH improvement
Not so much
First, a bacterial reverse mutation test (Ames test) assessed AOD9604s mutagenic potential using four histidine-dependent auxotrophic mutants of Salmonella typhimurium (TA1535, TA1537, TA98, TA100) and one tryptophan-dependent auxotrophic mutant of Escherichia coli (WP2 uvrA), using both plate incorporation and pre-incubation methods at doses of 0, 1.6, 8, 40, 200, 1,000, and 2,000 g AOD9604/plate
For those who prefer non-injectable options, oral Wegovy, with an average loss of 16.6% body weight, and Foundayo provide alternative solutions